Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 13/20 | 1.00 |
| ▸ | S100A4 | P26447 | 4/20 | 1.00 |
| ▸ | CDC25A | P30304 | 4/20 | 0.57 |
| ▸ | CDC25B | P30305 | 4/20 | 0.57 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721477 | 0.79 | SOAT1 (0.66) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL18191020 | 0.79 | SOAT1 (0.66) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL4762318 | 0.79 | SOAT1 (0.66) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL29018324 | 0.79 | SOAT1 (0.66) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL2599376 | 0.79 | SOAT1 (1.00) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL17250106 | 0.76 | SOAT1 (0.61) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL7106792 | 0.76 | SOAT1 (1.00) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL9713833 | 0.76 | SOAT1 (0.61) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL2599427 | 0.73 | SOAT1 (1.00) | SOAT1S100A4CDC25ACDC25BMAP2K7 | |
| SCHEMBL15732841 | 0.72 | SOAT1 (1.00) | SOAT1S100A4CDC25ACDC25BMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-04-11 | — | — | US | claimed |
| WO-2011146101-A1 | CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-24 | — | — | WO | claimed |
| CN-118697878-B | Application of CD36 as molecular marker for inhibiting lung cancer meninges metastasis and therapeutic target | 广东省人民医院 | 2025-02-11 | — | — | CN | disclosed |
| CN-118697878-A | Application of CD36 as molecular marker for inhibiting lung cancer meninges metastasis and therapeutic target | 广东省人民医院 | 2024-09-27 | — | — | CN | disclosed |
| CN-111116436-B | Synthetic method of thioether compound containing 1, 4-naphthoquinone structure | 信阳师范学院 | 2021-07-13 | — | — | CN | disclosed |
| CN-111116436-A | Synthetic method of thioether compound containing 1, 4-naphthoquinone structure | 信阳师范学院 | 2020-05-08 | — | — | CN | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3182129-B1 | METHOD OF SCREENING A THERAPEUTIC AGENT FOR K-RAS MUTANT CANCER | RAND BIO SCIENCE INC (KR) | 2018-12-26 | — | — | EP | disclosed |
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3182129-A1 | CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT | RAND Bio Science Inc. (KR) | 2017-06-21 | — | — | EP | disclosed |
| EP-2203161-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7691418-B2 | Composition for inhibiting or preventing the formation of a biofilm | OYSTERSHELL NV (BE) | 2010-04-06 | — | — | US | disclosed |
| WO-2009042544-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | OYSTERSHELL NV (BE) | 2007-11-08 | — | — | US | disclosed |
| EP-1796656-A2 | COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM | Oystershell NV (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029893-A2 | COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM | OYSTERSHELL NV (BE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005042442-A3 | 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005042442-A2 | 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Johannes Gutenberg-Universität Mainz (DE) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042442-A2 | 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Johannes Gutenberg-Universität Mainz (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | NQO2, NFKBIA, CROCC | SOAT1 932/4885S100A4 3710/4885CDC25A 1650/4885 |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | S100A4, S100A6, S100A10 | SOAT1 3535/4885S100A4 1/4885CDC25A 248/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | SOAT1 362/4885S100A4 2326/4885CDC25A 2032/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SOAT1 362/4885S100A4 1831/4885CDC25A 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.